Category: Our News
Creation of a global hub for RNA-based therapies in Quebec
Montreal, April 30, 2024. – The CQDM welcomes the announcement of the creation of an innovation hub for RNA-based therapies. This important mobilizing project is made possible thanks to a financial contribution of $20.3 million from the Government of Quebec (MEIE) and granted as part of the Stratégie québécoise des sciences de la vie (SQSV) 2022-2025.…
Announcement – Innovative Treatments for Diabetic Kidney Disease
CQDM, Roche, the Jewish General Hospital Foundation and McGill University fund research project of more than $9.4M on diabetic kidney disease Montreal, April 30, 2024 – CQDM is proud to announce the funding of a collaborative research project to identify biomarkers and therapeutic solutions for diabetic kidney disease (DKD), one of the leading causes of…
New Network Member: Simmunome
CQDM welcomes its new “Network” Member, Simmunome Inc.Simmunome untangles biological complexity by developing in silico disease models that accurately capture physiological processes to predict efficacy and safety of potential treatments. In addition, our algorithms use a comprehensive multiomic approach to discover new targets and biomarkers for a disease or a certain patient population. More information…
Welcome to Julia Serafino
CQDM. We grow. Welcome to Julia Serafino, our new Marketing and Communications Coordinator at CQDM! With a master’s degree in marketing and communications, Julia brings over 8 years of experience in the healthcare marketing sector. Before joining our team, she successfully worked for COLOPLAST, a medical devices laboratory, where she developed extensive skills in crafting…
Announcement – The therapeutic potential of a marine oxygen carrier
CQDM, HEMARINA Canada and Mitacs fund oncology research evaluating the therapeutic potential of a marine oxygen carrier Montreal, April 18, 2024 – CQDM is proud to announce the funding of a collaborative research project aimed at evaluating the therapeutic potential of a universal oxygen carrier from a marine organism in various oncology applications. This project,…
Announcement – Research project promoting cellular rejuvenation
CQDM, RejuvenRx and the fond Partenariat de l’Université de Montréal fund a research project promoting cellular rejuvenation. Montreal, April 9, 2024 – CQDM is proud to announce the funding of a collaborative research project led by Guy Sauvageau, Anne Marinier and RejuvenRx. Funding for this collaborative research project, for a total amount of $3,697,199, is…
Announcement – Development of a New Diagnostic Technique for Targeted Treatment of Breast Cancer
CQDM, Vega BioImagerie and Pfizer Canada Fund the Development of a New Diagnostic Technique for Targeted Treatment of Breast Cancer: Montreal, March 21, 2024 – CQDM is proud to announce the funding of a collaborative research project led by Michel Meunier, professor in the Department of Engineering Physics at Polytechnique Montréal, in partnership with Vega…
Treatment of Hirschsprung disease by rectal administration of neurotrophic factors.
Principal Investigator: Nicolas Pilon / Université du Québec à Montréal – UQAM Co-Investigators : Lekha Sleno / Université du Québec à Montréal – UQAM Project of $1 500 000 over 3 years Supported by CQDM through : Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE) And by co-funding partners: Neurenati The project in details : Challenge: …
Novel p53-activiting MDM2 inhibitor oncology platform therapy
Principal Investigator: François-Xavier Lacasse / UdeM Co-Investigators: John Sampalis, Ramy Saleh / RI-MUHC Gabi Hanna / Saydi Biotech Project of $3,342,000 over 3 years Supported by CQDM through: Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE) And by co-funding partners: Saydi Biotech The project in details: Challenge: All human cells have an…